7.40Open7.40Pre Close0 Volume45 Open Interest195.00Strike Price0.00Turnover131.71%IV25.87%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry7.40Extrinsic Value100Contract SizeAmericanOptions Type-0.1567Delta0.0031Gamma34.20Leverage Ratio-0.4656Theta-0.0239Rho-5.36Eff Leverage0.1419Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet